Ten years of changes in conditionning regimen for allogenic hematopoietic stem cell transplantation in adults;Evolution des conditionnements des greffes allogéniques de cellules souches hématopoïétiques chez l'adulte depuis 10 ans

Bulletin du Cancer

Volumn 95, Issue 1, 2008, Pages 87-97

  Peffault De Latour, Régis ^a   Cabrespine Faugeras, Aurélie ^b   Bay, Jacques Olivier ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔTEL DIEU   (France)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Myeloablative conditioning; Reduce intensity conditioning

Indexed keywords

ALEMTUZUMAB; AMSACRINE; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; MELPHALAN; RITUXIMAB; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW; FEASIBILITY STUDY; HODGKIN DISEASE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IRRADIATION; LOW DRUG DOSE; MYELODYSPLASIA; MYELOID LEUKEMIA; MYELOMA; REVIEW; SOLID TUMOR; TOXICITY; ADULT; AGE; BLOOD DISEASE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; MIDDLE AGED; RECURRENT DISEASE; WHOLE BODY RADIATION;

ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; RECURRENCE; TRANSPLANTATION CONDITIONING; WHOLE-BODY IRRADIATION;

EID: 39149110638     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0555     Document Type: Review

References (85)

1. Michallet M, Dhedin N, Michallet AS. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies]. Bull Cancer 2001 ; 88 : 908-26.
2. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006 ; 354 : 1813-26.
3. Faucher C. {Mini-allografts of bone marrow (hematology and solid tumors)}. Bull Cancer 2001 ; 88 : 110-3.
4. Maraninchi D, Gluckman E, Blaise D, Guyotat D, Rio B, Pico JL, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 1987 ; 2 : 175-8.
5. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990 ; 75 : 555-62.
6. Ringden O, Hermans J, Labopin M, Apperley J, Gorin NC, Gratwohl A. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and chronic leukaemia working parties of the European Group for Blood and Marrow Transplantation (EBMT). Leuk Lymphoma 1996 ; 24 : 71-9.
7. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989 ; 73 : 1720-8.
8. Weiden PL, Flournoy N, Sanders JE, Sullivan KM, Thomas ED. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplant Proc 1981 ; 13 : 248-51.
9. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995 ; 86 : 2041-50.
10. Michallet AS, Nicolini F, Michallet M. {Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT) : study of toxicity and efficacy}. Bull Cancer 2003 ; 90 : 758-62.
11. Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease : a critical effector role for interleukin-1. Transplant Proc 1993 ; 25 : 1216-7.
12. Champlin R, Khouri I, Komblau S, Molidrem J, Giralt S. Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect. Oncology (Williston Park) 1999 ; 13 : 621-8 ; (discussion 631, 635-628, 641).
13. Thomas ED, Buckner CD, Clift RA, Fefer A, Johnson FL, Neiman PE, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 1979 ; 301 : 597-9.
14. Brodsky RA, Chen AR, Brodsky I, Jones RJ. High-dose cyclophosphamide as salvage therapy for severe aplastic anemia. Exp Hematol 2004 ; 32 : 435-40.
15. Bacigalupo A. Third EBMT/Amgen Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant 2004 ; 33 : 691-6.
16. Michallet M, Bilger K, Garban F, Attal M, Huyn A, Blaise D, et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens : impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol 2001 ; 19 : 3340-9.
17. Basara N, Gunzelmann S, Willenbacher W, Fauser AA, Kiehl MG. New immunosuppressants in BMT/GVHD. Transplant Proc 2001 ; 33 : 2220-2.
18. Dean RM, Bishop MR. Graft-versus-host disease : emerging concepts in prevention and therapy. Curr Hematol Rep 2003 ; 2 : 287-94.
19. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003 ; 102 : 756-62.
20. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning : influence of pretransplantation comorbidities. Blood 2004 ; 104 : 961-8.
21. Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004 ; 104 : 1550-8.
22. Weissinger F, Sandmaier BM, Maloney DG, Bensinger WI, Gooley T, Storb R. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 2001 ; 98 : 3584-8.
23. Hogan WJ, Maris M, Storer B, Sandmaier BM, Maloney DG, Schoch HG, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation : a study of 193 patients. Blood 2004 ; 103 : 78-84.
24. Fukuda T, Hackman RC, Guthrie KA, Sandmaier BM, Boeckh M, Maris MB, et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2005 ; 102 : 2777-85.
25. Junghanss C, Marr KA, Carter RA, Sandmaier BM, Maris MB, Maloney DG, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation : a matched control study. Biol Blood Marrow Transplant 2002 ; 8 : 512-20.
26. Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002 ; 99 : 1978-85.
27. Weiss L, Reich S, Slavin S. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders : I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy. Cancer Invest 1992 ; 10 : 19-26.
28. Terenzi A, Aristei C, Aversa F, Perruccio K, Chionne F, Raymondi C, et al. Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning : preliminary results. Transplant Proc 1996 ; 28 : 3101.
29. Storb R, Yu C, Wagnet JL, Deeg HJ, Nash RA, Kiem HP, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997 ; 89 : 3048-54.
30. Storb R, Yu C, Barnett T, Wagner JL, Deeg HJ, Nash RA, et al. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 1999 ; 94 : 1131-6.
31. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies : replacing high-dose cytotoxic therapy wich graft-versus-tumor effects. Blood 2001 ; 97 : 3390-400.
32. Baron F, Sandmaier BM. Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. Curr Opin Hematol 2005 ; 12 : 435-43.
33. Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005 ; 23 : 3819-29.
34. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004 ; 104 : 3535-42.
35. Kerbauy DM, Chyou F, Gooley T, Sorror ML, Scott B, Pagel JM, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant 2005 ; 11 : 713-20.
36. Hallemeier C, Girgis M, Blum W, Brown R, Khoury H, Goodnough LT, et al. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants. Biol Blood Marrow Transplant 2004 ; 10 : 310-9.
37. Girgis M, Hallemeier C, Blum W, Brown R, Lin HS, Khoury H, et al. Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide. Blood 2005 ; 105 : 3035-41.
38. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, et al. Melphalan and purine analog-containing preparative regimens : reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001 ; 97 : 631-7.
39. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000 ; 96 : 2419-25.
40. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004 ; 104 : 3865-71.
41. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998 ; 91 : 756-63.
42. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003 ; 101 : 441-5.
43. Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004 ; 104 : 1616-23.
44. Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation : full donor T-cell chimerism precedes alloimmune responses. Blood 1999 ; 94 : 3234-41.
45. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000 ; 343 : 750-8.
46. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma : low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001 ; 98 : 3595-9.
47. Kassim AA, Chinratanalab W, Ferrara JL, Mineishi S. Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias : what is the best recipe? Bone Marrow Transplant 2005 ; 36 : 565-74.
48. Storb R, Leisenring W, Anasetti C, Appelbaum FR, Buckner CD, Bensinger WI, et al. Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. Blood 1997 ; 89 : 3890-1.
49. Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socié G, Maury S, et al. Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Fludarabine, cyclophosphamide and antithymocyte globulin for alternative donor transplants in acquired severe aplastic anemia : a report from the EBMT-SAA Working Party. Bone Marrow Transplant 2005 ; 36 : 947-50.
50. Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI, et al. Allogeneic marrow transplantation for refractory anemia : a comparison of two preparative regimens and analysis of prognostic factors. Blood 1996 ; 87 : 51-8.
51. Kroger N, Schetelig J, Zabelina T, Kruger W, Renges H, Stute N, et al. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant 2001 ; 28 : 643-7.
52. Parker JE, Shafi T, Pagliuca A, Mijovic A, Devereux S, Potter M, et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes : interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 2002 ; 119 : 144-54.
53. Socie G, Clift RA, Blaise D, Devergie A, Ringden O, Martin PJ, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia : long-term follow-up of 4 randomized studies. Blood 2001 ; 98 : 3569-74.
54. Feinstein LC, Sandmaier BM, Maloney DG, Maris MB, Gooley TA, Chauncey TR, et al. Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. Biol Blood Aiarrow Transplant 2003 ; 9 : 266-72.
55. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005 ; 23 : 5675-87.
56. Devergie A, Blaise D, Attal M, Tigaud JD, Jouet JP, Vernant JP, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase : a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen : a report from the French Society of Bone Marrow Graft (SFGM). Blood 1995 ; 85 : 2263-8.
57. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994 ; 84 : 2036-43.
58. Kroger N, Zabelina T, Kruger W, Renges H, Stute N, Kabisch H, et al. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Bone Marrow Transplant 2001 ; 27 : 349-54.
59. Clift RA, Radich J, Appelbaum FR, Martin P, Flowers ME, Deeg HJ, et al. Long-rerm follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 1999 ; 94 : 3960-2.
60. Biggs JC, Szer J, Crilley P, Atkinson K, Downs K, Dodds A, et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 1992 ; 80 : 1352-7.
61. Kebriaei P, Detry MA, Giralt S, Carrasco-Yalan A, Anagnostopoulos A, Couriel D, et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 2001 ; 110 : 3456-62.
62. Granados E, de La Camara R, Madero L, Diaz MA, Martin-Regueira P, Steegmann JL, et al. Hematopoietic cell transplantation in acute lymphoblastic leukemia : better long term event-free survival with conditioning regimens containing total body irradiation. Haematologica 2000 ; 85 : 1060-7.
63. Davies SM, Ramsay NK, Klein JP, Weisdorf DJ, Bolwell B, Cahn JY, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000 ; 18 : 340-7.
64. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation : an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002 ; 100 : 4310-6.
65. Peggs KS, Mackinnon S, Linch DC. The role of allogeneic transplantation in non-Hodgkin's lymphoma. Br J Haematol 2005 ; 128 : 153-68.
66. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991 ; 77 : 649-53.
67. Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease : the 21-year Seattle experience. J Clin Oncol 1993 ; 11 : 2342-50.
68. Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996 ; 14 : 572-8.
69. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996 ; 14 : 1291-6.
70. Akpek G, Ambinder RF, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB, et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001 ; 19 : 4314-21.
71. Anderlini P, Acholonu SA, Okoroji GJ, Andersson BS, Couriel DR, De Lima MJ, et al. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation : CD3 + cell dose, GVHD and disease response. Bone Marrow Transplant 2004 ; 34 : 511-4.
72. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease : low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005 ; 35 : 943-51.
73. Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma : results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006 ; 12 : 172-83.
74. Todisco E, Castagna L, Sarina B, Mazza R, Anastasia A, Balzarotti M, et al. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion. Eur J Haematol 2007 ; 78 : 322-9.
75. Schmitz N, Sureda A, Robinson S. Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin's disease : indications and results. Semin Oncol 2004 ; 31 : 27-32.
76. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med 1991 ; 325 : 1267-73.
77. Gahrton G, Tura S, Ljungman P, Blade J, Brandt L, Cavo M, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995 ; 13 : 1312-22.
78. Bensinger WI, Buckner CD, Anasetti C, Clift R, Storb R, Barnett T, et al. Allogeneic marrow transplantation for multiple myeloma : an analysis of risk factors on outcome. Blood 1996 ; 88 : 2787-93.
79. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Bjorkstrand B, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma : a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001 ; 113 : 209-16.
80. Kroger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002 ; 100 : 3919-24.
81. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, et al. Allografting wirh nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003 ; 102 : 3447-54.
82. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007 ; 356 : 1110-20.
83. Bay JO, Choufi B, Tournilhac O, Faucher C, Blaise D. {Allogeneic hematopoietic cell transplantation in solid tumors}. Bull Cancer 2001 ; 88 : 900-7.
84. Bay JO, Choufi B, Pomel C, Dauplat J, Durando X, Tournilhac O, et al. Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer. Bone Marrow Transplant 2000 ; 25 : 681-2.
85. Bay JO, Fleury J, Choufi B, Tournilhac O, Vincent C, Bailly C, et al. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma : results of five patients. Bone Marrow Transplant 2002 ; 30 : 95-102.